Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
495
Recruiting Now
495
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT06291207 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of AD-224
Condition
Hypertension,Essential
Enrollment
252 pts
Location
South Korea
Sponsor
Addpharma Inc.
NCT06618664 Phase 3
Recruiting
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Si...
Condition
Advanced Hepatocellular Carcinoma
Enrollment
590 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti
NCT04020263 Phase 3
Recruiting
Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Stra...
Condition
Cardiogenic Shock
Enrollment
610 pts
Location
France
Sponsor
Pr Bruno LEVY
NCT07321093 Phase 3
Recruiting
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitti...
Condition
Relapsing-remitting Multiple Sclerosis (RRMS)
Enrollment
292 pts
Location
Russia
Sponsor
Biocad
NCT06526533 Phase 3
Recruiting
RECOMMEND Platform Trial
Condition
Extracorporeal Membrane Oxygenation Complication
Enrollment
600 pts
Location
Australia
Sponsor
Australian and New Zealand Int
NCT05998187 Phase 3
Recruiting
Mechanisms of Action on Rectal Motricity of Intrarectal Botulinum Toxin Injectio...
Condition
Fecal Incontinence
Enrollment
21 pts
Location
France
Sponsor
University Hospital, Rouen
NCT05812807 Phase 3
Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who H...
Condition
Anatomic Stage II Breast Cancer AJCC v8
Enrollment
1,295 pts
Location
United States, Canada, Puerto Rico
Sponsor
Alliance for Clinical Trials i
NCT04094311 Phase 3
Recruiting
Study of Out of Specification for Tisagenlecleucel
Condition
B-cell Acute Lymphoblastic Leukemia
Enrollment
200 pts
Location
Canada, Japan
Sponsor
Novartis Pharmaceuticals
NCT07388498 Phase 3
Recruiting
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety,...
Condition
Uncontrolled Gout
Enrollment
270 pts
Location
United States, Puerto Rico
Sponsor
Amgen
NCT06522555 Phase 3
Recruiting
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients ...
Condition
Diffuse Large B-Cell Lymphoma
Enrollment
100 pts
Location
China
Sponsor
Ruijin Hospital
NCT06033950 Phase 3
Recruiting
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with ...
Condition
Heart Failure
Enrollment
2,600 pts
Location
United States, Brazil, Canada
Sponsor
Colorado Prevention Center
NCT06081959 Phase 3
Recruiting
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast C...
Condition
Metastatic Breast Cancer
Enrollment
376 pts
Location
China
Sponsor
Sichuan Kelun-Biotech Biopharm
NCT06408259 Phase 3
Recruiting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimo...
Condition
Multiple Sclerosis, Relapsing-Remitting
Enrollment
194 pts
Location
United States, Australia, Italy
Sponsor
Bristol-Myers Squibb
NCT06949033 Phase 3
Recruiting
Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diff...
Condition
Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])
Enrollment
668 pts
Location
China
Sponsor
Zuoyi Jiao
NCT07286058 Phase 3
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Condition
Psoriatic Arthritis
Enrollment
1,182 pts
Location
United States, Japan, Puerto Rico
Sponsor
Takeda
NCT04722978 Phase 3
Recruiting
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic T...
Condition
Triple Negative Breast Cancer
Enrollment
228 pts
Location
China
Sponsor
Sun Yat-Sen University Cancer
NCT06734260 Phase 3
Recruiting
Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacte...
Condition
Helicobacter Pylori Eradication Rate
Enrollment
477 pts
Location
China
Sponsor
Eighth Affiliated Hospital, Su
NCT05009082 Phase 3
Recruiting
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based C...
Condition
Ovarian Cancer
Enrollment
970 pts
Location
Germany
Sponsor
AGO Study Group
NCT06006117 Phase 3
Recruiting
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed...
Condition
Marginal Zone Lymphoma
Enrollment
260 pts
Location
Belgium, France, Germany
Sponsor
The Lymphoma Academic Research
NCT05597917 Phase 3
Recruiting
tTF-NGR Randomized Study - STS
Condition
Soft Tissue Sarcoma
Enrollment
126 pts
Location
Germany
Sponsor
Universität Münster
NCT06714838 Phase 3
Recruiting
Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating ...
Condition
CIDP
Enrollment
100 pts
Location
Netherlands
Sponsor
Amsterdam University Medical C
NCT06032559 Phase 3
Recruiting
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as...
Condition
Opioid Use
Enrollment
450 pts
Location
United States
Sponsor
Rutgers, The State University
NCT05834478 Phase 3
Recruiting
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Condition
Withdrawal Symptoms
Enrollment
103 pts
Location
United States
Sponsor
Emory University
NCT05800223 Phase 3
Recruiting
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non...
Condition
Non-small Cell Lung Cancer Metastatic
Enrollment
300 pts
Location
China
Sponsor
Shanghai Cancer Hospital, Chin
NCT05232279 Phase 3
Recruiting
Effect of Testofen on Erectile Function in an Adult Male Population
Condition
Erectile Dysfunction
Enrollment
120 pts
Location
Australia
Sponsor
RDC Clinical Pty Ltd
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology